1. Introduction {#sec1}
===============

The association between infectious agents and gastritis has been known for centuries. However, this relation was not strongly implicated until the discovery of *Helicobacter pylori* (*H. pylori*) in the early 1980s \[[@B1]\]. Since then, and in addition to gastritis, strong evidences have been accumulated regarding the role of *H. pylori* in multiple gastric disorders including peptic ulcer disease \[[@B2], [@B3]\], gastric cancer, and lymphoma \[[@B4], [@B5]\]. *H. pylori* is spiral-shape slow-growing gram-negative bacteria characterized by urease, catalase, and oxidase positivity \[[@B6]\]. Urease activity is crucial for bacterial survival, as well as constituting the basis of *H. pylori* diagnostic testing \[[@B7]\]. In developed countries, the *H. pylori* infection rate is low in childhood; however, it increases with age reaching 10 percent in adulthood and raising up to 50 percent in individuals older than 60 years \[[@B8], [@B9]\]. Low socioeconomic status, overcrowding, smoking, family member with *H. pylori*, and unfiltered drinking water were all shown to be directly associated with increased prevalence rates \[[@B10], [@B11]\]. The isolation of *H. pylori* from gastric secretions as well as stool culture explains transmissibility among family members \[[@B12]\]. Diagnostic tests of infection are classified as invasive and noninvasive and are based mainly on urease activity. Invasive tests include the urease test, culture, histology, and polymerase chain reaction (PCR) in which gastroscopy is required to obtain stomach tissue \[[@B7], [@B13], [@B14]\]. *H. pylori* infection, if not properly treated, leads to the insurgence of many digestive disorders, such as chronic gastritis, peptic ulcer, upper gastrointestinal bleeding, MALToma, chronic atrophic gastritis, intestinal metaplasia, and distal gastric adenocarcinoma, among others. Triple or quadruple antibiotic-based regimens are the mainstay of therapy. Detailed guidelines for the treatment of *H. pylori* infection were released by the American College of Gastroenterology (ACG) and the Maastricht Group \[[@B15], [@B16]\]. *H. pylori* and GERD are common gastrointestinal conditions in the general population and may coexist. The relationship between *H. pylori* and GERD symptoms and esophagitis is still controversial. Despite the fact that numerous papers showed a protective role of *H. pylori* against GERD and esophagitis \[[@B17], [@B18]\], one landmark meta-analysis showed inconsistent results \[[@B19]\]. The suggestive protective role has been related to decreased gastric acid secretion due to atrophic gastritis in patients infected with *H. pylori* \[[@B18]\]. Moreover, reports showed that eradication of *H. pylori* by restoring gastric acid secretion could exacerbate GERD symptoms \[[@B20]\]. Taking these controversies into consideration, we aimed in our study to characterize demographics and endoscopic findings in patients with GERD according to their *H. pylori* infection status.

2. Material and Methods {#sec2}
=======================

2.1. Ethical Clearance {#sec2.1}
----------------------

The current study received ethical approval from the local hospital ethical committee and was conducted according to the 1964 Helsinki declaration and its subsequent amendments. The data was coded in order to preserve the anonymity of the patients. Informed consent was waived because of the noninterventional design of the study.

2.2. Patient Selection {#sec2.2}
----------------------

All patients referred to the endoscopy unit at the EMMS Nazareth Hospital (a district university-affiliated hospital, Nazareth, Israel) for esophagogastroduodenoscopy (EGD) due to GERD symptoms such as heartburn and/or regurgitations or refractory GERD, typical symptoms, or the presence of alarm symptoms between the years 2015 and 2017 were considered potentially eligible and enrolled in the study. Patients were allocated retrospectively, through electronic medical reports at our unit software. All EGD procedures were performed at the single endoscopic unit, at the Nazareth Hospital, by five different senior gastroenterologists. Severity of esophagitis was assessed using the Los Angeles classification \[[@B21]\]. *H. pylori* infection was determined either by histological examination through a biopsy taken during the EGD or by the rapid urease test using commercially available kits in the unit (PyloPlis+ manufactured by Gulf Coast Medical Inc., Oldsmar, FL 34677, USA).

2.3. Statistical Analysis {#sec2.3}
-------------------------

Before proceeding with any statistical handling and processing, data were visually inspected for potential outliers. The assumption of normal distribution of data was checked conducting the D\'Agostino-Pearson omnibus test. Continuous data were expressed as means and standard deviations, whereas categorical parameters were computed as percentages, where appropriate.

Univariate analysis (chi-squared test, Student\'s *t*-test, and Kruskal-Wallis test) was performed to capture the main differences between subjects seronegative and seropositive for *H. pylori*.

Multivariate logistic or Poisson\'s regression analysis was conducted to shed light on the predictors of positivity for *H. pylori*, adjusting for potential confounders.

All statistical analyses were performed with the commercial software "Statistical Package for the Social Sciences" (SPSS version 24.0, IBM, Chicago, IL, USA). A *p* value of less than 0.05 was considered statistically significant.

3. Results {#sec3}
==========

A sample of 2,508 subjects with classical clinical GERD symptoms of heartburn and regurgitations, aged 49.42 ± 17.96 years, was included in the study: most were Arabs (83.7%), 52.4% were females, 66.7% were current smokers, and 10.3% had comorbidities. Concerning pharmacological treatment, 62.0% consumed PPIs, whereas 7.6% used statins. *H. pylori* infection was found positive in 299 patients (11.9%). For further details, the reader is referred to [Table 1](#tab1){ref-type="table"}.

In the univariate analysis ([Table 2](#tab2){ref-type="table"}), *H. pylori*-negative and *H. pylori*-positive patients differed for age (48.83 ± 17.42 years versus 44.57 ± 17.69 years, *p* ≤ 0.001), smoking status (1406 (63.6%) versus 266 (89.0%), *p* \> 0.001), and use of PPI (1314 (59.5%) versus 242 (80.9%), *p* ≤ 0.001), respectively. 70.6% of the *H. pylori*-non-infected group had no signs of esophagitis in endoscopy. 29.4% had esophagitis in the following LA classification severity order (17.2% had esophagitis LA A, 9.8% had esophagitis LA B, and 1.9% and 0.5% had LA D). In turn, 54.1% of the *H. pylori*-infected group had signs of esophagitis in endoscopy, in the following LA classification severity order (33.1% had esophagitis LA A, 9.7% had esophagitis LA B, 1.9% and 1.3% had LA C, and 0% had LA D). *H. pylori*-infected patients had less hiatus hernias (21.7%), compared to noninfected patients (30.7%).

In the multivariate logistic regression analysis ([Table 3](#tab3){ref-type="table"}), age (OR 0.987 (95%CI 0.980-0.994), *p* \< 0.001), smoking status (OR 0.190 (95%CI 0.112-0.324), *p* \< 0.001), use of aspirin/nonsteroidal anti-inflammatory drugs (ASA/NSAIDs) (OR 1.652 (95%CI 1.169-2.333), *p* = 0.004), and use of statins (OR 0.499 (95%CI 0.295-0.846), *p* = 0.010) were assessed.

Concerning the outcomes, *H. pylori*-infected and noninfected subjects differed in terms of insurgence (*p* \< 0.001) and severity (*p* = 0.003) of esophagitis ([Table 4(a)](#tab4a){ref-type="table"}) and insurgence of hiatal hernia (*p* = 0.001, [Table 4(b)](#tab4b){ref-type="table"}). No differences could be found in terms of prevalence of Barrett\'s esophagus.

Confirming the univariate analysis, the multivariate logistic regression shows that with respect to *H. pylori*-positive GERD patients, *H. pylori*-negative GERD individuals have a crude odds ratio (OR) of 1.598 (95%CI 1.196-2.134, *p* = 0.002) and a crude OR of 1.641 (95%CI 1.036-2.600, *p* = 0.035) of developing hiatal hernia ([Table 5](#tab5){ref-type="table"}). Conversely, they had a crude OR of 0.527 (95%CI 0.412-0.675, *p* \< 0.001) and an adjusted OR of 0.611 (95%CI 0.474-0.787, *p* \< 0.001) of developing esophagitis ([Table 6](#tab6){ref-type="table"}). Positivity for *H. pylori* impacted also on the severity of esophagitis (*p* = 0.047, [Table 7](#tab7){ref-type="table"}).

4. Discussion {#sec4}
=============

During the last decade, there has been a decrease in the prevalence of *H. pylori* infection; the prevalence of GERD, Barrett\'s esophagus, and esophageal adenocarcinoma has increased \[[@B22]\]. In our study, the prevalence of *H. pylori* infection among patients with symptoms suggestive of GERD was approximately 12%, which goes in parallel with the assumed inverse correlation between these two conditions. Chung et al. \[[@B23]\] showed in a Korean cohort of matched age and sex individuals lower prevalence of *H. pylori* infection in patients with GERD compared to controls. Furthermore, the authors reported that this association is negatively maintained throughout advanced grades of esophagitis, therefore suggesting a protective role of *H. pylori* against GERD. Indeed, our study found similar findings showing that advanced stages of esophagitis are less prevalent in patients with GERD and with *H. pylori* infection.

Epidemiological studies worldwide showed *H. pylori* infection to be acquired earlier in life in developing countries in opposite to developed countries where infection peaks after the age of 60 \[[@B24]\]. The median age of patients with GERD enrolled in our study differed among *H. pylori*-infected and noninfected individuals. *H. pylori*-infected patients were much younger than noninfected persons indicating an earlier acquisition of infection. Our findings suggest closer pictures to developing world. In terms of ethnicity, in contrast to the findings of Everhart et al. \[[@B25]\] that Blacks and Hispanics were found to have a higher prevalence of *H. pylori* infection, we found no difference in both groups analyzed. The authors concluded this ethnic variation to be probably explained by differences in socioeconomic status.

Relationship between smoking status and *H. pylori* infection has given contrasting findings in the literature \[[@B26]\]. Ogihara and collaborators found that current smokers had a 0.82- (95%CI 0.74-0.91) fold greater risk of *H. pylori* infection than those who had never smoked, with current cigarette consumption exhibiting a dose-dependently negative association with *H. pylori* \[[@B27]\]. This association was strong in younger subjects. Authors postulated that smoking-induced increased gastric acidity could play a major role in leading to *H. pylori* infection. Furthermore, polymorphisms could explain the relationship between smoking status and *H. pylori* \[[@B28]\]. On the other hand, Zhang and coauthors failed to find a statistically significant relationship between smoking status and *H. pylori* infection. Our data showed significantly higher smoking rates among *H. pylori*-positive individuals compared to negative persons \[[@B29]\].

In our study, alcohol drinking was not associated with *H. pylori* infection. In other studies, such as that by Ogihara and coworkers, current drinkers had a 0.88- (95%CI 0.79-0.98) fold greater risk of *H. pylori* infection than those who had never consumed alcohol \[[@B28]\].

Giral et al. \[[@B23]\] showed that PPI use in patients infected with *H. pylori* was associated with greater inhibition of gastric acid secretion when compared to uninfected individuals. Similar findings were demonstrated by Verdu et al.; by this manner, our data showed that *H. pylori*-infected patients have significantly greater proportion of PPI use. These findings have two main implications. First, while PPI is a guideline-recommended part of therapy, when it is used on top of *H. pylori* infection, it leads to substantially higher degrees of acid secretion inhibition. Second, while inhibition of gastric acid secretion seems to explain the protective role of *H. pylori* infection against GERD and higher degrees of esophagitis, this explains the lower prevalence rate of advanced grades of esophagitis in *H. pylori*-infected individuals. As shown in this, we saw our findings as going consistent with previous studies in medical literature.

While infection of *H. pylori* is assumed to be protective against GERD, the presence of hiatal hernia after eradication of *H. pylori* contributes to the development of GERD \[[@B30]\]. In our study, most of the patients enrolled had no hiatal hernia. Taking into consideration the presence of symptoms of GERD in all patients enrolled, hiatal hernia was more common in *H. pylori*-negative patients. This sheds light on the pathogenetic correlation between GERD and *H. pylori* in the presence of hiatal hernia.

Our study, when compared to similar studies in the literature, has several strong points: a large cohort of patients with well-defined characteristics, as well as a quite uniform ethnic homogeneity, as this prevents possible bias. Another point is that patients were screened endoscopically due to GERD symptoms including not only those with esophagitis but also those who were previously diagnosed with GERD as this permitted a larger cohort to be included.

The retrospective manner of the study and operator-dependent endoscopy and the clinical diagnosis of GERD without having PH monitoring to confirm acid reflux are all part of our limitations.

In conclusion, patients with GERD who tested positive for *H. pylori* were younger, tend to smoke more, and use more PPI than those who tested negative. In addition, patients infected with *H. pylori* had more esophagitis; however, they had less severe esophagitis compared to noninfected patients.
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###### 

Descriptive statistics of the sample studied.

  Parameter                 Value (*n* = 2,508)
  ------------------------- ---------------------
  Ethnicity                 
   Arabs                    2,100 (83.7%)
   Jews                     408 (16.3%)
  BMI                       29.67 ± 7.02, 29.0
  Sociodemographic status   
   Rural                    1,524 (60.8%)
   Urban                    984 (39.2%)
  Age                       49.42 ± 17.96, 50.0
  Gender                    
   Males                    1,194 (47.6%)
   Females                  1,314 (52.4%)
  Smoking status            1,672 (66.7%)
  Alcohol consumption       96 (3.8%)
  Comorbidities             259 (10.3%)
  ASA/NSAID users           680 (27.1%)
  Statin users              190 (7.6%)
  PPI users                 1,556 (62.0%)

ASA: acetylsalicylic acid; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.

###### 

Values broken down according to *Helicobacter pylori* infection status (univariate analysis).

  Parameter                        Subjects without *H. pylori* infection (*n* = 2,209)                        Subjects with *H. pylori* infection (*n* = 299)                            *p* value
  -------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------
  Ethnicity                                                                                                                                                                               0.157
   Arabs (*n* = 2,100)             1,841 (83.3% of *H. pylori* subjects, 87.7% of Arabs)                       259 (86.6% of *H. pylori* subjects, 12.3% of Arabs)                        
   Jews (*n* = 408)                368 (16.7% of *H. pylori* subjects, 90.2% of Jews)                          40 (13.4% of *H. pylori* subjects, 9.8% of Jews)                           
  BMI                              29.69 ± 7.67                                                                29.91 ± 6.29                                                               0.297
  Sociodemographic status                                                                                                                                                                 0.256
   Rural (*n* = 1,524)             1,333 (60.3% of *H. pylori* subjects, 87.5% of rural subjects)              191 (63.9% of *H. pylori* subjects, 12.5% of rural subjects)               
   Urban (*n* = 984)               876 (39.7% of *H. pylori* subjects, 89.0% of urban subjects)                108 (36.1% of *H. pylori* subjects, 11.0% of urban subjects)               
  Age                              48.83 ± 17.42                                                               44.57 ± 17.69                                                              *p* ≤ 0.001
  Gender                                                                                                                                                                                  0.902
   Males (*n* = 1,194)             1,053 (47.7% of *H. pylori* subjects, 88.2% of males)                       141 (47.2% of *H. pylori* subjects, 11.8% of males)                        
   Females (*n* = 1,314)           1,156 (52.3% of *H. pylori* subjects, 88.0% of females)                     158 (52.8% of *H. pylori* subjects, 12.0% of females)                      
  Smoking status (*n* = 1,672)     1,406 (63.6% of *H. pylori* subjects, 84.1% of smokers)                     266 (89.0% of *H. pylori* subjects, 15.9% of smokers)                      *p* ≤ 0.001
  Alcohol consumption (*n* = 96)   82 (3.7% of *H. pylori* subjects, 85.4% of alcohol consumers)               14 (4.7% of *H. pylori* subjects, 14.6% of alcohol consumers)              0.421
  Comorbidities (*n* = 259)        222 (10.0% of *H. pylori* subjects, 85.7% of subjects with comorbidities)   37 (12.4% of *H. pylori* subjects, 14.3% of subjects with comorbidities)   0.224
  ASA/NSAID users (*n* = 680)      613 (27.8% of *H. pylori* subjects, 90.1% of ASA/NSAID users)               67 (22.4% of *H. pylori* subjects, 9.9% of ASA/NSAID users)                0.052
  Statin users (*n* = 190)         164 (7.4% of *H. pylori* subjects, 86.3% of statin users)                   26 (8.7% of *H. pylori* subjects, 13.7% of statin users)                   0.416
  PPI users (*n* = 1,556)          1,314 (59.5% of *H. pylori* subjects, 84.4% of PPI users)                   242 (80.9% of *H. pylori* subjects, 15.6% of PPI users)                    *p* ≤ 0.001

ASA: acetylsalicylic acid; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.

###### 

Predictors of *Helicobacter pylori* infection (multivariate logistic regression analysis).

  Parameter                       OR      95%CI OR           
  ------------------------------- ------- ---------- ------- -------
  Ethnicity (Arabs versus Jews)   1.105   0.765      1.595   0.596
  BMI                             1.002   0.988      1.017   0.747
  Rural versus urban              1.144   0.883      1.481   0.308
  Age                             0.987   0.980      0.994   0.001
  Gender                          1.008   0.786      1.293   0.951
  Smoking status                  0.190   0.112      0.324   0.001
  Alcohol consumption             0.773   0.425      1.406   0.398
  Comorbidities                   0.781   0.534      1.143   0.203
  ASA/NSAID users                 1.652   1.169      2.333   0.004
  Statin users                    0.499   0.295      0.846   0.010
  PPI users                       1.116   0.716      1.741   0.627
  Constant                        0.567                      0.301

ASA: acetylsalicylic acid; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.

###### 

\(a\) Endoscopic findings of GERD (insurgence and severity of esophagitis) subjects stratified according to the *Helicobacter pylori* (*H. pylori*) infection status

  *H. pylori* status (*n* = 2.508)     No esophagitis (*n* = 1,726)   Esophagitis (*n* = 782)                            
  ------------------------------------ ------------------------------ ------------------------- ------------ ----------- -----------
  *H. pylori* negative (*n* = 2,209)   1,559 (70.6%)                  379 (17.2%)               216 (9.8%)   43 (1.9%)   12 (0.5%)
  *H. pylori* positive (*n* = 299)     167 (55.9%)                    99 (33.1%)                29 (9.7%)    4 (1.3%)    0 (0.0%)

###### 

\(b\) Outcomes of subjects with GERD symptoms (insurgence of hiatal hernia) stratified according to their *Helicobacter pylori* infection status

  *H. pylori* status (*n* = 2,508)     No hiatal hernia (*n* = 1,764)                                                            Hiatal hernia (*n* = 744)
  ------------------------------------ ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  *H. pylori* negative (*n* = 2,209)   1,530 (69.3% of *H. pylori*-negative subjects, 86.7% of subjects without hiatal hernia)   679 (30.7% of *H. pylori*-negative subjects, 91.3% of subjects with hiatal hernia)
  *H. pylori* positive (*n* = 299)     234 (78.3% of *H. pylori*-positive subjects, 13.3% of subjects without hiatal hernia)     65 (21.7% of *H. pylori*-positive subjects, 8.7% of subjects with hiatal hernia)

###### 

Determinants of insurgence of hiatal hernia in GERD patients (multivariate logistic regression analysis).

  Parameter                                       OR        95%CI OR             
  ----------------------------------------------- --------- ---------- --------- -------------
  *H. pylori* status (negative versus positive)   1.641     1.036      2.600     0.035
  Ethnicity (Arabs versus Jews)                   0.993     0.685      1.441     0.972
  BMI                                             1.000     0.982      1.018     0.968
  Rural versus urban                              0.768     0.583      1.012     0.061
  Age                                             1.014     1.006      1.022     0.001
  Gender                                          0.950     0.724      1.248     0.713
  Smoking status                                  0.916     0.539      1.555     0.745
  Alcohol consumption                             0.955     0.480      1.903     0.897
  Comorbidities                                   0.730     0.484      1.102     0.134
  ASA/NSAID users                                 0.001     0.001      0.002     *p* ≤ 0.001
  Statin users                                    253.885   89.148     723.041   *p* ≤ 0.001
  PPI users                                       0.591     0.346      1.007     0.053
  Constant                                        0.334                          0.074

ASA: acetylsalicylic acid; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.

###### 

Determinants of insurgence of esophagitis in GERD patients (multivariate logistic regression analysis).

  Parameter                                       OR      95%CI OR           
  ----------------------------------------------- ------- ---------- ------- -------------
  *H. pylori* status (negative versus positive)   0.611   0.474      0.787   *p* ≤ 0.001
  Ethnicity (Arabs versus Jews)                   0.786   0.622      0.995   0.045
  BMI                                             0.995   0.982      1.007   0.395
  Rural versus urban                              0.957   0.801      1.143   0.629
  Age                                             0.997   0.992      1.002   0.242
  Gender                                          1.199   1.007      1.426   0.041
  Smoking status                                  0.370   0.265      0.519   *p* ≤ 0.001
  Alcohol consumption                             0.859   0.551      1.339   0.503
  Comorbidities                                   0.768   0.584      1.011   0.060
  ASA/NSAID users                                 0.779   0.629      0.965   0.022
  Statin users                                    1.209   0.831      1.761   0.321
  PPI users                                       1.359   0.990      1.866   0.058
  Constant                                        1.913                      0.120

ASA: acetylsalicylic acid; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.

###### 

Determinants of severity of esophagitis in GERD patients (Poisson\'s regression analysis).

  Parameter                                       *B*      SE       Wald\'s chi-square   Sig.
  ----------------------------------------------- -------- -------- -------------------- -------
  Constant                                        0.027    0.2868   0.009                0.925
  Ethnicity (Arabs versus Jews)                   0.082    0.0799   1.062                0.303
  Rural versus urban                              −0.012   0.0607   0.039                0.843
  Gender                                          0.002    0.0596   0.001                0.971
  Smoking status                                  0.036    0.1146   0.096                0.756
  Alcohol consumption                             0.018    0.1494   0.015                0.902
  Comorbidities                                   0.041    0.0919   0.202                0.653
  ASA/NSAID users                                 −0.018   0.0710   0.067                0.796
  Statin users                                    0.028    0.1285   0.046                0.830
  PPI users                                       −0.086   0.1038   0.693                0.405
  *H. pylori* status (negative versus positive)   0.168    0.0847   3.956                0.047
  BMI                                             0.001    0.0048   0.001                0.996
  Age                                             0.002    0.0017   1.779                0.182

ASA: acetylsalicylic acid; BMI: body mass index; NSAIDs: nonsteroidal anti-inflammatory drugs; PPIs: proton pump inhibitors.
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